the Journal of Clinical Oncology
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
Every single patient with advanced pancreatic cancer who walked into Dr. Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy. Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to fail.
Cancer survivors may see surprising benefits from one specific exercise, study says
For many, surviving cancer comes with an automatic new lease on life but other survivors continue to experience physical and emotional challenges long after treatment ends. Yoga may significantly reduce the insomnia, fatigue and mood disturbances many survivors endure after remission, a recent clinical trial found. Mood disturbance and insomnia are "two of the most pervasive and troubling side effects experienced by cancer survivors for years after completing adjuvant treatments," the...
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.
The secret reason some cancer treatments stop working
The secret reason some cancer treatments stop working - Date: - June 9, 2026 - Source: - University of Montreal - Summary: - Scientists have uncovered a hidden immune system "brake" that may help cancers avoid being destroyed. The molecule, called SLAMF6, weakens the body's cancer-fighting T cells and can leave them exhausted over time. Researchers developed antibodies that block this brake, allowing immune cells to stay stronger and attack tumors more effectively in mice.
A single protein may be holding back CAR T cancer therapy
A single protein may be holding back CAR T cancer therapy - Date: - June 2, 2026 - Source: - University Hospital Tübingen - Summary: - A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival A once-“undruggable” pancreatic cancer target has finally been cracked, and the new treatment nearly doubled survival in a landmark trial. - Date: - June 4, 2026 - Source: - The Conversation - Summary: -
Biohybrid microrobots repair spinal cord by combining stem cells with magnetoelectric nanoparticles
Biohybrid microrobots repair spinal cord by combining stem cells with magnetoelectric nanoparticles Sadie Harley Scientific Editor Robert Egan Associate Editor Spinal cord injuries can have devastating consequences for those affected. Nerve cells in the spinal cord rarely regenerate naturally, while scarring often prevents the regrowth of nerve fibers. Modern therapies attempt to influence implanted stem cells using electrical stimulation to promote the growth of new nerve cells.